)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
DURECT
DURECT (DRRX) investor relations material
DURECT has been acquired by Bausch Health Companies Inc
DURECT Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary12 Aug, 2025
Executive summary
Entered into a definitive agreement for acquisition by Bausch Health at $1.75/share plus up to $350M in milestone CVRs, with closing expected in Q3 2025.
Lead drug larsucosterol showed positive trends in Phase 2b for alcohol-associated hepatitis and received FDA Breakthrough Therapy and Fast Track designations.
Completed sale of ALZET product line in November 2024 for $17.5M, now classified as discontinued operations.
Ongoing operations focus on epigenetic therapies and select excipient product sales.
Financial highlights
Q2 2025 total revenues were $447K, down from $646K in Q2 2024; six-month revenues were $768K, down from $1.1M year-over-year.
Net loss from continuing operations was $2.3M for Q2 2025, down from $3.7M in Q2 2024; six-month net loss was $6.5M, down from $11.3M year-over-year.
Cash, cash equivalents, and investments totaled $6.7M at June 30, 2025, compared to $12.0M at December 31, 2024.
Operating expenses for Q2 2025 were $3.25M, down from $4.84M in Q2 2024.
Research and development expenses for Q2 2025 were $1.2M, down from $2.2M in Q2 2024; SG&A expenses were $2.1M, down from $2.6M.
Outlook and guidance
Management expects research and development and SG&A expenses to remain comparable or decrease in the near term.
Company anticipates continued operating losses and negative cash flows; substantial doubt exists about ability to continue as a going concern without additional funding.
Pending merger restricts ability to raise capital or pursue strategic transactions until closing.
Merger with Bausch Health expected to close in Q3 2025, subject to regulatory and shareholder approvals.
Potential for up to $350M in milestone payments tied to larsucosterol sales if achieved by 2045.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from DURECT
- Q3 revenue up, cash down, and Phase 3 larsucosterol trial awaits funding amid partner exits.DRRX
Q3 2024 - Larsucosterol advances after FDA breakthrough status; Q2 loss narrows but cash concerns persist.DRRXQ2 2024
- Q1 2025 net loss narrowed as plans for a Phase 3 larsucosterol trial hinge on new funding.DRRXQ1 2025
- Larsucosterol shows promise in reducing mortality for alcohol-associated hepatitis; phase III awaits funding.DRRXOppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025
- Debt-free after ALZET sale, seeking $20M for Phase 3 larsucosterol trial; funding is critical.DRRXQ4 2024
DURECT
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
DURECT Corp is a biopharmaceutical company engaged in the development of therapies using epigenetic modulation for the treatment of acute organ injury and chronic liver diseases. Its research focuses on new chemical entities, with a significant emphasis on its endogenous epigenetic regulator program. The company's pipeline includes products such as DUR-928, aimed at conditions like alcoholic hepatitis and nonalcoholic steatohepatitis (NASH); Posimir, designed for post-operative pain management; and Oradur, for chronic pain and attention deficit hyperactivity disorders. Additionally, DURECT manufactures and markets osmotic pumps for laboratory research and provides biodegradable polymers and excipients for the pharmaceutical and medical device industries. The company is headquartered in Cupertino, California, and its shares are listed on the Nasdaq.